本页面由Tiger Trade Technology Pte. Ltd.提供服务

Tarsus Pharmaceuticals, Inc.

70.65
-0.8000-1.12%
成交量:61.16万
成交额:4,324.41万
市值:31.00亿
市盈率:-65.27
高:71.15
开:71.10
低:69.77
收:71.45
52周最高:85.25
52周最低:48.20
股本:4,388.30万
流通股本:3,267.99万
量比:1.06
换手率:1.87%
股息:- -
股息率:- -
每股收益(TTM):-1.0824
每股收益(LYR):-1.5900
净资产收益率:-13.68%
总资产收益率:-5.48%
市净率:8.94
市盈率(LYR):-44.43

数据加载中...

2023/06/08

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/06/07

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/06/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/10

关联方拟减持公告

144 - Report of proposed sale of securities
2023/05/09

重要事件披露

8-K - Current report
2023/05/09

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/05

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/05/01

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/28

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/24

重要事件披露

8-K - Current report
2023/04/21

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/20

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/19

关联方拟减持公告

144 - Report of proposed sale of securities
2023/04/13

SEC问询函

Form CORRESP - Correspondence
2023/03/17

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/17

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/16

关联方拟减持公告

144 - Report of proposed sale of securities
2023/03/16

关联方拟减持公告

144 - Report of proposed sale of securities